Riehen, Switzerland

Hans Blattner

This inventor holds 7 USPTO granted patents. Top assignee: Ciba-Geigy Corporation. Active years: 1976-1987.


% Patents Active = 100.0

Average Co-Inventor Count = 1.6

ph-index = 2

Forward Citations = 16(Granted Patents)


Company Filing History:


Years Active: 1976-1987

Loading Chart...
7 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Hans Blattner

Introduction

Hans Blattner is a notable inventor based in Riehen, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that address various states of agitation. With a total of 7 patents to his name, Blattner's work has had a considerable impact on the medical community.

Latest Patents

Blattner's latest patents include innovative treatments for states of agitation using azatetracyclic compounds. These compounds are designed to serve as tranquillizing, antipsychotic, and excitation-inhibiting agents. Specific embodiments of these compounds include 3-methyl-2,3,4,5-tetrahydro-1H-dibenzo[2,3:6,7]thiepino[4,5-d]azepine and 3-methyl-2,3,4,5-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-d]azepine. Additionally, he has developed azatetracyclic carbonitriles that exhibit central nervous system-depressant properties, making them suitable for treating agitated states caused by various factors.

Career Highlights

Throughout his career, Hans Blattner has been associated with Ciba-Geigy Corporation, a prominent player in the pharmaceutical industry. His work has focused on creating compounds that not only alleviate agitation but also provide therapeutic benefits for patients suffering from mental health issues.

Collaborations

Blattner has collaborated with various professionals in his field, including his coworker Angelo Storni. Their combined efforts have contributed to the advancement of pharmaceutical innovations.

Conclusion

Hans Blattner's contributions to the field of pharmaceuticals through his innovative patents have made a significant impact on the treatment of agitation and related conditions. His work continues to influence the development of effective therapeutic agents.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…